In summary, this work offers a new interesting perspective on myeloid leukemias treatment; in particular our data highlight β3-AR as an attractive target to reduce cancer cell survival in myeloid malignancies (Figure 7). This evidence concerns the gene ADRB3 and myeloid neoplasm.